Table 1. Characteristics of Patients (N = 673), by Type of Definitively Treated HNC.
| Characteristic | Nasopharynx (n = 227) | HPV-positive oropharynx (n = 237) | HPV-negative oropharynx (n = 47) | Hypopharynx (n = 65) | Larynx (n = 97) |
|---|---|---|---|---|---|
| Age, median (range), y | 52 (15-81) | 59 (37-81) | 63 (49-77) | 66 (47-83) | 64 (40-82) |
| Men | 168 (74.0) | 203 (85.7) | 43 (91.5) | 54 (83.1) | 87 (89.7) |
| Women | 59 (26.0) | 34 (14.3) | 4 (8.5) | 11 (16.9) | 10 (10.3) |
| Performance status | |||||
| ECOG 0-1 | 222 (97.8) | 237 (100) | 45 (95.7) | 56 (86.2) | 85 (87.6) |
| ECOG ≥2 | 5 (2.2) | 0 | 2 (4.3) | 9 (13.8) | 12 (12.4) |
| Tumor stage | |||||
| T1 | 72 (31.7) | 58 (24.5) | 8 (17.0) | 7 (10.8) | 7 (7.2) |
| T2 | 47 (20.7) | 124 (52.3) | 22 (46.8) | 27 (41.5) | 15 (15.5) |
| T3 | 43 (18.9) | 29 (12.2) | 8 (17.0) | 13 (20.0) | 51 (52.6) |
| T4 | 65 (28.6) | 26 (11.0) | 9 (19.2) | 18 (27.7) | 24 (24.7) |
| Nodule stage | |||||
| N0 | 28 (12.3) | 8 (3.4) | 2 (4.3) | 15 (23.1) | 45 (46.4) |
| N1 | 88 (38.8) | 88 (37.1) | 19 (40.4) | 9 (13.9) | 14 (14.4) |
| N2 | 94 (41.4) | 136 (57.4) | 25 (53.2) | 40 (61.5) | 38 (39.2) |
| N3 | 17 (7.5) | 5 (2.1) | 1 (2.1) | 1 (1.5) | 0 |
| Treatment | |||||
| Definitive CCRT | 146 (64.3) | 81 (34.2) | 21 (44.7) | 32 (49.2) | 56 (57.7) |
| Induction chemotherapy and CCRT | 81 (35.7) | 66 (27.9) | 14 (29.8) | 18 (27.7) | 19 (19.6) |
| Surgery and adjuvant RT | 0 | 42 (17.7) | 6 (12.8) | 7 (10.8) | 17 (17.5) |
| Surgery and adjuvant CCRT | 0 | 48 (20.3) | 6 (12.8) | 8 (12.3) | 5 (5.2) |
| RT dose, median (range), Gy | 67.5 (60.0-72.0) | 67.5 (57.0-72.0) | 67.5 (60.0-70.0) | 67.5 (60.0-70.0) | 67.5 (59.4-70.0) |
| Follow-up period, median (range), mo | 59.0 (6.4-157.2) | 58.8 (6.8-158.1) | 51.0 (10.1-135.6) | 52.9 (8.0-148.3) | 54.2 (13.5-156.5) |
Abbreviations: CCRT, concurrent chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; HNC, head and neck cancer; HPV, human papillomavirus; RT, radiotherapy.